
Nuo Therapeutics: Biotech firm innovating regenerative therapies for wound care and inflammation.
nuot.comCrawled Sep 25, 2026
Nuo Therapeutics is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing.
Nuo Therapeutics releases its second-quarter 2026 financial results, highlighting growth in its differentiated autologous PRP (platelet-rich plasma) therapies. The company emphasizes long-term market potential for its regenerative medicine solutions, targeting unmet needs in orthopedics and aesthetics. Financial details and operational updates are provided in the earnings report.
Aug 2026GlobeNewswireNews article
Nuo Therapeutics reports first-quarter 2026 financial results highlighting strong growth for its Aurix product line. The company updates stakeholders on business progress, though specific metrics or details remain undisclosed in the announcement.
May 2026BioSpaceNews article
Nuo Therapeutics reports its first-quarter 2026 financial performance and outlines key business developments. The biotech company highlights progress in its pipeline, including preclinical programs targeting neurodegenerative diseases. Nuo Therapeutics also emphasizes strategic partnerships and operational milestones achieved in the quarter.
May 2026GlobeNewswireNews article
Nuo Therapeutics secures an exclusive private-label distribution deal with Smith+Nephew for its biodynami medical device technology. The agreement positions Nuo’s innovations under Smith+Nephew’s established brand while leveraging Nuo’s commercial-stage expertise. This partnership expands Nuo’s market reach in advanced wound care and regenerative medicine solutions.
Apr 2025The National Law ReviewNews article